Evidence map›Paper›PMID 22130959›Full record

ArticleInternational urology and nephrology2012

Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients?

J Malyszko, J S Malyszko, N Levin-Iaina, E Koc-Zorawska, P Kozminski, M Mysliwiec

Abstract read
In one paragraph

Article in International urology and nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Biomarkers of iron metabolism in chronic kidney disease.International urology and nephrology · 2021
    Review
  3. Article
  4. Iron dosing in kidney disease: inconsistency of evidence and clinical practice.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015
    Review
  5. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2014
    Review
  6. Article
  7. Diagnosis of anaemia: old things rearranged.Wiener medizinische Wochenschrift (1946) · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

J MalyszkoDepartment of Nephrology and Transplantology, Medical University, Bialystok, Poland. jolmal@poczta.onet.pl
J S Malyszko
N Levin-Iaina
E Koc-Zorawska
P Kozminski
M Mysliwiec

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHemojuvelin (HJV) is highly expressed in the liver, skeletal muscles, and heart, seems to play a role in iron absorption and release from cells, and has anti-inflammatory properties. Moreover, HJV plays an essential role in the regulation of hepcidin expression, specifically in the iron-sensing pathway. Hepcidin has emerged as a key regulator of iron homeostasis. In this study we tested for the first time the hypothesis that HJV is related to iron metabolism in hemodialysis (HD) patients.

methodsIron status, complete blood count, and serum creatinine, albumin, and lipids were assessed, using standard laboratory methods. Serum levels of soluble transferrin receptor (sTFR), high-sensitivity CRP, IL-6, hepcidin, and HJV were measured using commercially available kits.

resultsSerum HJV, hepcidin, ferritin, IL-6, hsCRP, and serum creatinine were significantly higher (all P<0.001), whereas serum iron, sTFR, transferrin, hemoglobin, and erythrocyte count were significantly lower in HD patients, compared to healthy volunteers (all P<0.001). In univariate analysis, HJV was strongly correlated (P<0.001) with ferritin, transferrin saturation, and TIBC, as well as with hsCRP, hepcidin, Kt/V (P<0.01) and residual renal function, the presence of diabetes, APKD, and coronary heart disease. Predictors of HJV level in multiple regression analysis were ferritin (beta value was 0.50, P=0.00004) and transferrin saturation (beta value was 0.47, P=0.0002), explaining 81% of the HJV variations.

conclusionsSerum HJV is elevated in HD patients and related predominantly to kidney function and iron metabolism. However, HJV is probably not correlated to inflammation. HJV appears to be a new player in iron metabolism in these patients.

Indexed as

Renal DialysisAntimicrobial Cationic PeptidesGPI-Linked ProteinsHemochromatosis ProteinHepcidinsHumansIronMiddle AgedAntimicrobial Cationic PeptidesGPI-Linked ProteinsHAMP protein, humanHemochromatosis ProteinHepcidinsHJV protein, humanIron

Identifiers

PMID22130959
PMCPMC3510395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.